Breakdown | |||||
TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
1.74M | 0.00 | 700.00K | 1.42M | 0.00 | 0.00 | Gross Profit |
604.00K | -1.21M | -11.24M | -550.00K | -665.00K | -666.00K | EBIT |
-48.53M | -43.57M | -58.06M | -63.01M | -49.97M | -47.95M | EBITDA |
-47.33M | -42.37M | -56.70M | -61.87M | -48.87M | -46.79M | Net Income Common Stockholders |
-46.13M | -42.21M | -58.95M | -63.16M | -49.74M | -45.99M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
7.01M | 44.37M | 61.14M | 28.61M | 20.48M | 25.40M | Total Assets |
0.00 | 59.15M | 77.88M | 54.25M | 41.29M | 41.91M | Total Debt |
0.00 | 9.14M | 75.96M | 11.25M | 11.36M | 6.72M | Net Debt |
7.01M | -35.22M | 14.82M | -17.36M | -1.11M | -180.00K | Total Liabilities |
0.00 | 14.79M | 80.13M | 18.56M | 18.40M | 11.18M | Stockholders Equity |
16.07M | 44.36M | -2.25M | 35.69M | 22.89M | 30.74M |
Cash Flow | Free Cash Flow | ||||
-34.09M | -33.16M | -47.41M | -54.53M | -35.81M | -34.79M | Operating Cash Flow |
-33.98M | -33.04M | -47.01M | -54.10M | -35.37M | -34.19M | Investing Cash Flow |
-115.00K | -121.00K | -401.00K | 7.56M | 10.04M | -10.10M | Financing Cash Flow |
62.74M | 16.39M | 79.94M | 62.69M | 30.89M | 82.00K |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
67 Neutral | $173.51M | 13.35 | 11.29% | 2.29% | -18.56% | -13.66% | |
55 Neutral | $1.18B | ― | -6.14% | ― | -20.89% | 83.44% | |
53 Neutral | $889.34M | 55.81 | -5.16% | ― | -2.64% | -193.31% | |
51 Neutral | $5.32B | 3.32 | -40.25% | 2.90% | 17.93% | 2.14% | |
50 Neutral | $234.79M | 25.27 | -4.64% | ― | -54.17% | -135.78% | |
48 Neutral | $1.20B | ― | -67.31% | ― | ― | -1.00% |
Pulse Biosciences announced the appointment of Jon Skinner as Chief Financial Officer, effective February 3, 2025, to bolster its executive team as it scales the commercialization of its CellFX nanosecond PFA platform. Skinner, with extensive experience in financial leadership across healthcare and industrial sectors, brings strategic insights that are expected to aid in advancing Pulse Biosciences’ operational excellence and market positioning.